Larisa Geskin, MD
Dermatology · New York, NYNPI 1063485050
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $178,951 of the $239,723 with a category attached, or 74.6%. 21 manufacturers reported payments, led by Helsinn Healthcare SA at 52.7% of the total. Reporting peaked in 2019 at $89,901 and has fallen 86.3% since, to $12,355 in 2025. Among dermatology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $1507.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Helsinn Healthcare SA$126K
- Helsinn Therapeutics (U.S.), Inc.$33K
- Regeneron$32K
- Kyowa Kirin, Inc.$16K
- Takeda$12K
- Sanofi$7K
- plus $12K from 15 others
Across 445 payments — averaging $2625.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$544K
- Kyowa Kirin, Inc.$425K
- Mallinckrodt Hospital Products Inc.$138K
- Takeda Pharmaceuticals U.S.A., Inc.$22K
- Kyowa Kirin Services Ltd$22K
- Innate Pharma, Inc$16K
- plus $1K from 1 others
What the payments were for
- Consulting fees$178,95175%
- Speaking & faculty fees$14,1446%
- Travel & lodging$42,49018%
- Food & beverage$4,0712%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Helsinn Healthcare SA | 37 | $126,298 |
| Helsinn Therapeutics (U.S.), Inc. | 28 | $33,261 |
| Regeneron | 2 | $32,430 |
| Kyowa Kirin, Inc. | 42 | $16,419 |
| Takeda | 1 | $12,100 |
| Sanofi | 7 | $7,057 |
| Mallinckrodt Hospital Products Inc. | 4 | $3,976 |
| Daiichi Sankyo Inc. | 1 | $3,083 |
| Eisai Inc. | 1 | $2,400 |
| Dr.reddy's Laboratories,inc. | 1 | $1,500 |
| Johnson & Johnson | 16 | $523 |
| Therakos LLC | 1 | $140 |
| Regeneron Healthcare Solutions, Inc. | 6 | $133 |
| AbbVie | 5 | $128 |
| E.r. Squibb & Sons, L.L.C. | 1 | $71 |
| Bausch Health US, LLC | 1 | $67 |
| Sun Pharmaceutical Industries Inc. | 1 | $34 |
| Mallinckrodt Enterprises LLC | 1 | $33 |
| Pfizer | 1 | $27 |
| Galderma Laboratories, L.p. | 1 | $25 |
| Novartis | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$239,723 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValchlorMechlorethamine Hcl | 80 | $623,727 |
| CopiktraDuvelisib | 12 | $333,066 |
| Dupixent SyringeDupilumab | 74 | $272,791 |
| Bexarotene | 13 | $186,153 |
| RinvoqUpadacitinib | 18 | $136,755 |
| Dupixent PenDupilumab | 18 | $64,018 |
| OzempicSemaglutide | 13 | $11,618 |
| Fluorouracil | 88 | $5,934 |
| Ketoconazole | 392 | $5,858 |
| Tacrolimus | 25 | $4,772 |
| Clobetasol Propionate | 75 | $4,431 |
| Calcipotriene | 20 | $3,280 |
| Metronidazole | 58 | $2,592 |
| Imiquimod | 84 | $2,513 |
| Ammonium Lactate | 136 | $2,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Helsinn Healthcare SAValchlor | $126,298 | $623,72780 claims |
| AbbVieRinvoq | $128 | $136,75518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- George HanNew York$1.6M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.